Fig 1: Increased SRSF1 expression in proliferating VSMCs in vivo and in vitro.(a) Photomicrographs of haematoxylin/eosin-stained carotid arteries from sham-operated and balloon-injured rats. Immunohistochemical staining of vessels with specific anti-SRSF1 antibody revealed SRSF1 mainly in the neointima (N, neointima; M, media). Normal rabbit IgG served as a negative control. Scale bars, 50 μm. (b) Immunofluorescence double staining of injured carotid arteries with specific antibodies against SM-α-actin (green) or SRSF1 (red). Nuclei were stained with DAPI (blue), and yellow indicates their co-localization in the merged images. Scale bars, 50 μm. (c) Real-time PCR showing the mRNA levels of SRSF1 in carotid arteries at 1, 4, 7, 14 and 21 days after balloon injury; n=8 per group. (d) Representative western blots and averaged data showing SRSF1 and PCNA levels in rat carotid arteries at 1, 4, 7, 14 and 21 days after balloon injury; n=8 per group. (e) Real-time PCR data showing the mRNA levels of SRSF1 in HASMCs treated with Ang II (200 nM), serum (10% FBS) or PDGF-BB (10 μg l−1) at 6, 12 and 24 h; n=8 per group. (f) Representative western blots and averaged data showing SRSF1 levels in HASMCs treated as in e; n=7 per group. *P<0.05, **P<0.01, one-way ANOVA (c–f). Data are mean±s.e.m. of five independent experiments (c–f).
Fig 2: Δ133p53 promotes neointima formation after vascular injury.(a,b) Hematoxylin/eosin staining (a) and averaged data (b) of the neointimal area, neointima/media ratio, media area, and circumference of external elastic lamina (EEL) of rat carotid arteries transfected with indicated adenovirus 2 weeks postinjury (N, neointima; M, media); n=8 each; scale bar, 50 μm. (c) PCNA staining and PCNA-positive cells in rat carotid arteries treated as in (a) 2 weeks postinjury. Arrows indicate PCNA-positive cells; n=8 each; scale bar, 25 μm. (d) Δ133p53 siRNAs (Δ133 si1 and Δ133 si2) knock down Δ133p53 level in HASMCs; n=8. (e–g) PCNA level (e), MTT assays (f) and wound-healing assays (g) in HASMCs infected with Δ133p53 siRNAs after Ang II stimulation; (e), n=8; (f), n=11; (g), n=9. (h) PCNA levels in HASMCs infected with Δ133p53 siRNAs in the presence or absence of Ad-SRSF1; n=6. (i) MTT assays showing SRSF1-mediated enhancement of proliferation was inhibited by Δ133p53 knockdown; n=12. (j) Averaged data from wound-healing assays in HASMCs infected with Δ133p53 siRNAs in the presence or absence of Ad-SRSF1 and treated with Ang II; n=8. All adenoviral infection in HASMCs above is 100 m.o.i. for 48 h. Ang II is 200 nM. Scr indicates scrambled siRNA. *P <0.05, **P<0.01, NS, not significant; one-way ANOVA (b–j), Data are mean±s.e.m. of five (b–e,h) or four (f,g,i,j) independent experiments.
Fig 3: SRSF1-triggered activation of KLF5 requires EGR1 binding to Δ133p53.(a) Co-immunoprecipitation (IP) assay identified interaction between Δ133p53 and EGR1. Cell lysates from HASMCs infected with Ad-β-gal or Ad-Δ133p53-myc were immunoprecipitated with antibody to myc (left) or EGR1 (right) and detected with western blots. Input lysates were loaded as control; n=5 per group. (b) Chromatin immunoprecipitation (ChIP) assays were performed to detect the recruitment of EGR1 protein to the promoter of KLF5 after overexpression of Δ133p53. HASMCs were infected with Ad-β-gal or Ad-Δ133p53-myc. Crosslinked DNA–protein lysates are immunoprecipitated with antibody to EGR1. The fragments containing consensus EGR1-binding motifs are PCR amplified from both samples. Four distinct EGR1-binding positions (P1, P2, P3 and P4) in KLF5 are shown. n=9 per group. (c) Representative western blots and averaged data showing the EGR1 levels in HASMCs infected with scrambled or two sets of EGR1 siRNAs (EGR1 si1 and EGR1 si2). (d) ChIP assays were performed in HASMCs infected with Ad-β-gal or Ad-Δ133p53-myc in the presence or absence of EGR1 siRNA1 (EGR1 si); n=9 per group. Crosslinked DNA–protein lysates from infected cells are immunoprecipitated with EGR1 antibody. The P1 and P2 promoter fragments (same as Fig. 7b) containing EGR1-binding motifs are PCR amplified from both samples. (e) Representative western blots and averaged data showing KLF5, p21 and PCNA levels in HASMCs transfected with EGR1 siRNAs with or without Ad-SRSF1 overexpression; n=7 per group. (f) Representative western blots and averaged data showing KLF5, p21 and PCNA levels in HASMCs transfected with EGR1 siRNAs with or without Ad-Δ133p53 overexpression; n=9 per group. (g,h) The proliferation enhancement induced by SRSF1 (g) or Δ133p53 (h) was attenuated by EGR1 siRNAs; n=12 per group. Scr indicates scrambled siRNA control. *P<0.05, **P<0.01, NS, not significant; Student’s t-test (b) or one-way ANOVA (d–h). Data are mean±s.e.m. of four (b,d) or five (e–h) independent experiments.
Fig 4: Development and validation of APEX-Phase Separation (APEX-PS) for enrichment of subcellular RNA-binding proteins (RBPs).a In the first step of APEX-PS, 1 min APEX-catalyzed biotinylation is carried out, followed by 10 min of RNA–protein crosslinking in living cells. Red B, biotin. RBP, RNA-binding protein. b In the second step of APEX-PS, phase separation of cell lysate from a localizes crosslinked protein–RNA complexes to the interphase, while free proteins and RNA localize to the organic and aqueous phases, respectively. After washing, RNA-crosslinked proteins are released from the interphase by RNase treatment and subjected to streptavidin bead-based enrichment of biotinylated proteins. c Streptavidin blotting reveals enrichment of nuclear RBPs by APEX-PS. Biotinylation and formaldehyde crosslinking were performed in HEK293T cells expressing nuclear-localized APEX (APEX-NLS). Streptavidin blotting was performed on total cell lysate (left), samples after phase separation (middle), and samples after both phase separation and streptavidin enrichment (right). d Western blot detection of known nuclear RBPs in samples from c. SRSF1 and hnRNPC are true-positive nuclear RBPs, GRSF1 is a mitochondrial RBP, and ETS2 is a nuclear protein that does not bind RNA (non-RBP).
Fig 5: SRSF1 promotes VSMC proliferation via KLF5–p21 signal.(a) Venn diagram of modulated genes in HASMCs overexpressing Δ133p53 and treated with Ang II, showing 247 genes that fit the criteria of >0.5 FPKM (fragments per kilobase of exon per million fragments mapped) and an adjusted P-value of <0.05 (Wald tests implemented in the DESeq R package), commonly modulated in both conditions. (b,c) The mRNA levels (b) and protein abundance (c) of KLF5 in HASMCs with Δ133p53 overexpression or Δ133p53 knockdown; n=7–8 per group. (d,e) KLF5 expression in HASMCs with SRSF1 overexpression or SRSF1 knockdown at mRNA level (d) and protein level (e); n=6 per group. (f) Cell-cycle distributions in HASMCs infected with Ad-SRSF1 in the absence or presence of KLF5 siRNA stimulated with Ang II (200 nM) for 24 h; n=9 per group. (g) KLF5 siRNAs (KLF5 si1 and KLF5 si2) knock down KLF5 protein in HASMCs; n=8 per group. (h) Expression of p21 in HASMCs infected with Ad-SRSF1 or Ad-Δ133p53; n=5 per group. (i) p21 levels in HASMCs with SRSF1 knockdown or Δ133p53 knockdown; n=7 per group. (j) PCNA and p21 levels in HASMCs infected with KLF5 siRNAs in the absence or presence of Ad-SRSF1; n=7 per group. (k) KLF5 and p21 levels in HASMCs infected with Δ133p53 siRNAs (Δ133 si1 and Δ133 si2) in the presence or absence of Ad-SRSF1; n=7 per group. (l,m) KLF5 and p21 levels in cultured HASMCs infected with SRSF1 siRNAs (l) or Δ133p53 siRNAs (m) after Ang II stimulation (200 nM, 24 h); n=5–7 per group. (n) KLF5 and p21 levels in the arteries from Srsf1−/− or WT control mice; n=7 per group. (o) KLF5 and p21 levels in rat carotid arteries transfected with Ad-SRSF1 1 week after balloon injury; n=10 per group. Scr indicates scrambled siRNA control; BI, balloon injury. *P<0.05, **P<0.01, one-way ANOVA (b–f,h–m,o) or Student’s t-test (n). Data are mean±s.e.m. of four (b,d) or five (c,e–o) independent experiments.
Supplier Page from Abcam for Anti-SF2 antibody [EPR8239]